 |
This is a Live Event. View this activity to register.
|
With the recent approval of many novel agents there have been significant changes in the treatment landscape for melanoma. Surgical oncologists, plastic surgeons, and ENT and general surgeons play a crucial role in the diagnosis, staging, and management of melanoma.
 |
This is a Grand Rounds Program
|
This new CME-certified in-hospital grand rounds program provides clinicians with information on new frontline treatment options for multiple myeloma and insights on how they can be integrated into their practices to improve patient outcomes.
| |
This is a Grand Rounds Program
|
This new CME-certified in-hospital grand rounds program provides clinicians with information on emerging agents in Her2-positive breast cancer and how they can be integrated into their practices to improve patient outcomes.
| |
This is a Grand Rounds Program
|
This new CME-certified in-hospital grand rounds program provides clinicians with information on emerging strategies in relapsed/refractory non-hodgkin’s lymphoma and how they can be integrated into their practices to improve patient outcomes.
 |
Program Type
 |
This CME/CE certified webcourse is designed to increase awareness of the role of gender in the individualization of care for NSCLC patients. Current best practices that can improve outcomes are explored.
 |
Program Type
|
This case-based webcourse reviews the diagnosis and classification of sarcomas and the timing for referral to a specialty center; explains the updated NCCN clinical guidelines for diagnosis and treatment and how to plan a multidisciplinary treatment approach; and discusses ongoing trials and emerging data from novel treatment regimens.
 |
Program Type
|
Non-small cell lung cancer (NSCLC) can no longer be considered a homogenous disease. Histologic and molecular features of NSCLC provide important prognostic information and predict response to targeted therapy; therefore, therapy must be individualized according to these criteria to maximize patient outcomes.
 |
Program Type
|
Non-small cell lung cancer (NSCLC) can no longer be considered a homogenous disease. Histologic and molecular features of NSCLC provide important prognostic information and predict response to targeted therapy; therefore, therapy must be individualized according to these criteria to maximize patient outcomes.
 |
Program Type
|
Non-small cell lung cancer (NSCLC) can no longer be considered a homogenous disease. Histologic and molecular features of NSCLC provide important prognostic information and predict response to targeted therapy; therefore, therapy must be individualized according to these criteria to maximize patient outcomes.
 |
Program Type
|
Non-small cell lung cancer (NSCLC) can no longer be considered a homogenous disease. Histologic and molecular features of NSCLC provide important prognostic information and predict response to targeted therapy; therefore, therapy must be individualized according to these criteria to maximize patient outcomes.
 |
Program Type
|
Non-small cell lung cancer (NSCLC) can no longer be considered a homogenous disease. Histologic and molecular features of NSCLC provide important prognostic information and predict response to targeted therapy; therefore, therapy must be individualized according to these criteria to maximize patient outcomes.
OPTIMIZING THE CONTINUUM OF CARE FOR MYELODYSPLASTIC SYNDROMES
|
| A series of four multidisciplinary webcourses on the diagnosis and treatment of patients with myelodysplastic syndromes (MDS). |
| • Making A Definitive Diagnosis of MDS |
Learn More |
| • Anemia Differentiation in the Elderly: When to Refer |
Learn More |
| • Management of Patients with IPSS Low/Int-1-Risk MDS |
Learn More |
| • Management of Patients with IPSS Int-2/High Risk MDS |
Learn More |
TARGETING GIST: EVOLVING THERAPY
|
|
This CME-certified online monograph reviews the distinct management strategies that have emerged for patients with primary GIST that can easily be surgically removed as well as for those with locally advanced, recurrent, or metastatic GIST.
|
| Learn More |
THE EVOLVING ROLE OF MICROTUBULE INHIBITORS IN ADVANCED BREAST CANCER
|
|
This CME-certified webcourse reviews the current and emerging clinical data to define best practices for the management of patients with advanced breast cancer using microtubule-inhibitors.
|
| Learn More |